Department of Pharmaceutical Science and Technology, College of Chemistry and Biology, Donghua University, Shanghai 201620, China.
Shanghai Xianhui Pharmaceutical Co., Ltd., Shanghai 200433, China.
Bioorg Chem. 2020 Aug;101:104042. doi: 10.1016/j.bioorg.2020.104042. Epub 2020 Jun 26.
A series of new fluoro-substituted benzimidazole derivatives were designed, synthesized and pharmacologically evaluated. All the target compounds were characterized by HNMR, CNMR, mass spectra and elemental analysis. The biological evaluation showed that most of the synthesized compounds displayed nanomolar affinity to the angiotensin II type 1 (AT) receptor and could decrease blood pressure efficiently in spontaneously hypertensive rats. The maximal response of mean blood pressure (MBP) lowered 74.5 ± 3.5 mmHg (1g) and 69.2 ± 0.9 mmHg (2a) at 10 g/kg after oral administration, and the antihypertensive effect lasted beyond 24 h, which performed better than both losartan and telmisartan. So, compounds 1g and 2a may be considered as potential antihypertension drug candidates.
一系列新的氟取代苯并咪唑衍生物被设计、合成并进行了药理学评价。所有目标化合物均通过 HNMR、CNMR、质谱和元素分析进行了表征。生物评价表明,大多数合成化合物对血管紧张素 II 型 1(AT)受体具有纳摩尔亲和力,并能有效降低自发性高血压大鼠的血压。化合物 1g 和 2a 在口服 10g/kg 后,平均血压(MBP)的最大反应分别降低了 74.5±3.5mmHg 和 69.2±0.9mmHg,降压作用持续超过 24 小时,优于氯沙坦和替米沙坦。因此,化合物 1g 和 2a 可能被认为是有潜力的抗高血压药物候选物。